Ebola Drug Could Save a Few Lives. But Whose? - 5 views
-
miriambachman on 02 Sep 14This article not only touches upon the dangerous and negative effects of the Ebola outbreak, but calls into questions an ethical controversy regarding preferential treatment when it comes to medical care. As the need for a cure escalates, the time allotted for the testing and developing of an anti-Ebola drug diminishes. Thus, medicine that has not been thoroughly tested has been distributed to two white Americans infected with the virus. This begs the question: Why these two? Does it have to do with their race or anti-African biases? And once the drug is fully developed, who will receive the treatment first? Who will be prioritized? Additionally, this contentious matter has added to the already distrustful African view of Western pharmaceuticals and relief efforts.
- ...2 more comments...
-
dredd15 on 04 Sep 14I found it interesting that not only did the article touch on the ethical questions of who to give the first available drugs to, from a standpoint of where it would be most effective rather than just where it would be most convenient. The part of the article where acceptance of the drug came into question was another touchy matter. The attempt to administer the drug as a solution to the Ebola break out is difficult because of the nature of the illness and the apprehension towards Western Medicine. Even though the medicine is available there's no telling if this quick fix will actually contain and solve the crisis just as Arthur Kaplan says at the end of the article.
-
aaron_godinez on 04 Sep 14The article brings to light interesting conflicts between African countries and the western industries of medicine. I feel like it would be effective to offer medical education to the local inhabitants in the infected african countries. That way their knowledge can help them avoid getting the disease. Furthermore, they would have more knowledge to help them decide whether or not they would like to take the drug that is possibly a functioning vaccination, rather than just not giving the sick African patients the option. The complexity of this problem is interesting because it deals with issues of ethics and trust.